Literature DB >> 21496616

Wilson's disease.

Ronald F Pfeiffer1.   

Abstract

In the almost 100 years since Wilson's description of the illness that now bears his name, tremendous advances have been made in our understanding of this disorder. The genetic basis for Wilson's disease - mutation within the ATP7B gene - has been identified. The pathophysiologic basis for the damage resulting from the inability to excrete copper via the biliary system with its consequent gradual accumulation, first in the liver and ultimately in the brain and other organs and tissues, is now known. This has led to the development of effective diagnostic and treatment modalities that, although they may not eliminate the disorder, do provide the means for efficient diagnosis and effective amelioration if carried out in a dedicated and persistent fashion. Nevertheless, Wilson's disease remains both a diagnostic and treatment challenge for physician and patient. Its protean clinical manifestations make diagnosis difficult. Appropriate diagnostic evaluations to confirm the diagnosis and institute treatment can be confusing. In this chapter, the clinical manifestations, diagnostic evaluation, and treatment approaches for Wilson's disease are discussed.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21496616     DOI: 10.1016/B978-0-444-52014-2.00049-5

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  13 in total

Review 1.  Insights into the management of Wilson's disease.

Authors:  Mohmadshakil Kathawala; Gideon M Hirschfield
Journal:  Therap Adv Gastroenterol       Date:  2017-10-03       Impact factor: 4.409

2.  Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease.

Authors:  Marialuisa Quadri; Antonio Federico; Tianna Zhao; Guido J Breedveld; Carla Battisti; Cathérine Delnooz; Lies-Anne Severijnen; Lara Di Toro Mammarella; Andrea Mignarri; Lucia Monti; Antioco Sanna; Peng Lu; Francesca Punzo; Giovanni Cossu; Rob Willemsen; Fabrizio Rasi; Ben A Oostra; Bart P van de Warrenburg; Vincenzo Bonifati
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

3.  Lenticular nucleus hyperechogenicity in Wilson's disease reflects local copper, but not iron accumulation.

Authors:  Uwe Walter; Marta Skowrońska; Tomasz Litwin; Grażyna Maria Szpak; Katarzyna Jabłonka-Salach; David Skoloudík; Ewa Bulska; Anna Członkowska
Journal:  J Neural Transm (Vienna)       Date:  2014-03-11       Impact factor: 3.575

4.  Childhood dystonias.

Authors:  Samer D Tabbal
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

5.  Infantile Ascending Hereditary Spastic Paralysis with Extrapyramidal and Extraocular Manifestations Associated with a Novel ALS2 Mutation.

Authors:  Govind Madhaw; Niraj Kumar; Divya M Radhakrishnan; Ritu Shree
Journal:  Mov Disord Clin Pract       Date:  2021-11-28

Review 6.  Movement Disorders and the Gut: A Review.

Authors:  Lauren S Talman; Ronald F Pfeiffer
Journal:  Mov Disord Clin Pract       Date:  2022-02-05

7.  Copper ions stimulate the proliferation of hepatic stellate cells via oxygen stress in vitro.

Authors:  San-Qing Xu; Hui-Yun Zhu; Jian-Guo Lin; Tang-Feng Su; Yan Liu; Xiao-Ping Luo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

8.  Distinct phenotype of a Wilson disease mutation reveals a novel trafficking determinant in the copper transporter ATP7B.

Authors:  Lelita T Braiterman; Amrutha Murthy; Samuel Jayakanthan; Lydia Nyasae; Eric Tzeng; Grazyna Gromadzka; Thomas B Woolf; Svetlana Lutsenko; Ann L Hubbard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

Review 9.  The Pragmatic Treatment of Wilson's Disease.

Authors:  Annu Aggarwal; Mohit Bhatt
Journal:  Mov Disord Clin Pract       Date:  2014-04-10

10.  Urinary copper elevation in a mouse model of Wilson's disease is a regulated process to specifically decrease the hepatic copper load.

Authors:  Lawrence W Gray; Fangyu Peng; Shannon A Molloy; Venkata S Pendyala; Abigael Muchenditsi; Otto Muzik; Jaekwon Lee; Jack H Kaplan; Svetlana Lutsenko
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.